114 related articles for article (PubMed ID: 31860086)
1. STAT5: From Pathogenesis Mechanism to Therapeutic Approach in Acute Leukemia.
Shahjahani M; Abroun A; Saki N; Bagher Mohammadi SM; Rezaeeyan H
Lab Med; 2020 Jul; 51(4):345-351. PubMed ID: 31860086
[TBL] [Abstract][Full Text] [Related]
2. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
3. Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.
Müller TA; Grundler R; Istvanffy R; Rudelius M; Hennighausen L; Illert AL; Duyster J
Leukemia; 2016 Aug; 30(8):1725-33. PubMed ID: 27046463
[TBL] [Abstract][Full Text] [Related]
4. The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia.
Cao T; Jiang N; Liao H; Shuai X; Su J; Zheng Q
Sci Rep; 2019 Aug; 9(1):12209. PubMed ID: 31434952
[TBL] [Abstract][Full Text] [Related]
5. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
[TBL] [Abstract][Full Text] [Related]
6. Indole-3-carbinol induces apoptosis of chronic myelogenous leukemia cells through suppression of STAT5 and Akt signaling pathways.
Safa M; Jafari L; Alikarami F; Manafi Shabestari R; Kazemi A
Tumour Biol; 2017 Jun; 39(6):1010428317705768. PubMed ID: 28631564
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.
Chatterjee A; Ghosh J; Ramdas B; Mali RS; Martin H; Kobayashi M; Vemula S; Canela VH; Waskow ER; Visconte V; Tiu RV; Smith CC; Shah N; Bunting KD; Boswell HS; Liu Y; Chan RJ; Kapur R
Cell Rep; 2014 Nov; 9(4):1333-48. PubMed ID: 25456130
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
[TBL] [Abstract][Full Text] [Related]
9. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
10. STAT5-dependent regulation of CDC25A by miR-16 controls proliferation and differentiation in FLT3-ITD acute myeloid leukemia.
Sueur G; Boutet A; Gotanègre M; Mansat-De Mas V; Besson A; Manenti S; Bertoli S
Sci Rep; 2020 Feb; 10(1):1906. PubMed ID: 32024878
[TBL] [Abstract][Full Text] [Related]
11. Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia.
Heltemes-Harris LM; Larson JD; Starr TK; Hubbard GK; Sarver AL; Largaespada DA; Farrar MA
Oncogene; 2016 Jun; 35(26):3454-64. PubMed ID: 26500062
[TBL] [Abstract][Full Text] [Related]
12. STAT5 gene polymorphisms are associated with the response of acute myeloid leukemia patients to Ara-C-based chemotherapy.
Xu P; Zhou D; Ouyang J; Chen B
Leuk Lymphoma; 2016; 57(4):921-6. PubMed ID: 26384082
[TBL] [Abstract][Full Text] [Related]
13. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
Elife; 2016 Nov; 5():. PubMed ID: 27879203
[TBL] [Abstract][Full Text] [Related]
14. Targeting of STAT5 using the small molecule topotecan hydrochloride suppresses acute myeloid leukemia progression.
Li J; Tang B; Miao Y; Li G; Sun Z
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37830151
[TBL] [Abstract][Full Text] [Related]
15. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
Yamada O; Ozaki K; Furukawa T; Machida M; Wang YH; Motoji T; Mitsuishi T; Akiyama M; Yamada H; Kawauchi K; Matsuoka R
Cell Signal; 2011 Jul; 23(7):1119-27. PubMed ID: 21356308
[TBL] [Abstract][Full Text] [Related]
16. New Inhibitor Targeting Signal Transducer and Activator of Transcription 5 (STAT5) Signaling in Myeloid Leukemias.
Juen L; Brachet-Botineau M; Parmenon C; Bourgeais J; Hérault O; Gouilleux F; Viaud-Massuard MC; Prié G
J Med Chem; 2017 Jul; 60(14):6119-6136. PubMed ID: 28654259
[TBL] [Abstract][Full Text] [Related]
17. Identification of the UBA2-WTIP fusion gene in acute myeloid leukemia.
Lu X; Zhuang H; Yu Q; Zhang X; Wu Z; Zhang L; Xu Y; Wu B; Yang L; Ma A; Gan X; Yu X; Shen J; Xu R
Exp Cell Res; 2018 Oct; 371(2):409-416. PubMed ID: 30179602
[TBL] [Abstract][Full Text] [Related]
18. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
[TBL] [Abstract][Full Text] [Related]
19. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
[TBL] [Abstract][Full Text] [Related]
20. Stat5-deficient hematopoiesis is permissive for Myc-induced B-cell leukemogenesis.
Wang Z; Medrzycki M; Bunting ST; Bunting KD
Oncotarget; 2015 Oct; 6(30):28961-72. PubMed ID: 26338970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
